BridgeBio Pharma (BBIO) Competitors

BioNTech (NASDAQ:BNTX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Which has higher valuation and earnings, BNTX or BBIO?

BridgeBio Pharma has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.98B	8.93	-$719.92M	-$3.40	-32.54
BridgeBio Pharma	$221.90M	40.19	-$535.76M	-$3.53	-13.31

Is BNTX or BBIO more profitable?

BioNTech has a net margin of -27.37% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-27.37%	-3.94%	-3.41%
BridgeBio Pharma	-524.25%	N/A	-94.43%

Which has more volatility and risk, BNTX or BBIO?

BioNTech has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.

Do insiders & institutionals believe in BNTX or BBIO?

15.5% of BioNTech shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 18.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media prefer BNTX or BBIO?

In the previous week, BridgeBio Pharma had 5 more articles in the media than BioNTech. MarketBeat recorded 19 mentions for BridgeBio Pharma and 14 mentions for BioNTech. BioNTech's average media sentiment score of 0.99 beat BridgeBio Pharma's score of 0.82 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate BNTX or BBIO?

BioNTech currently has a consensus target price of $137.91, suggesting a potential upside of 24.64%. BridgeBio Pharma has a consensus target price of $61.20, suggesting a potential upside of 30.30%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83
BridgeBio Pharma	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

BridgeBio Pharma beats BioNTech on 9 of the 17 factors compared between the two stocks.